All Outputs (15)

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience (2023)
Journal Article
Shotton, R., Broadbent, R., Alchawaf, A., Mohamed, M. B., Gibb, A., Martinez-Calle, N., …Linton, K. M. (2023). Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience. Blood Advances, 8(4), 878-888. https://doi.org/10.1182/bloodadvances.2023011305

Bendamustine is among the most effective chemotherapeutics for indolent B-cell non- Hodgkin lymphomas (iNHL), but trial reports of significant toxicity, including opportunistic infections and excess deaths, led to prescriber warnings. We conducted a... Read More about Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma (2023)
Journal Article
Lewis, K. L., Jakobsen, L. H., Villa, D., Smedby, K. E., Savage, K. J., Eyre, T. A., …Pophali, P. A. (2023). High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma. Journal of Clinical Oncology, 41(35), 5376-5387. https://doi.org/10.1200/JCO.23.00365

PURPOSE CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There is no consensus regarding the optimal approach to CNS prophylaxis. This study was designed to determine whether high-dose methotrexat... Read More about High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.

Management of secondary central nervous system lymphoma (2022)
Journal Article
Cwynarski, K., Cummin, T., Osborne, W., Lewis, J., Chaganti, S., Smith, J., …the British Society for Haematology (BSH) Committee. (2023). Management of secondary central nervous system lymphoma. British Journal of Haematology, 200(2), 160-169. https://doi.org/10.1111/bjh.18539

Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management (2022)
Journal Article
Tse, E., Fox, C. P., Glover, A., Yoon, S. E., Kim, W. S., & Kwong, Y. L. (2022). Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management. Seminars in Hematology, 59(4), 198-209. https://doi.org/10.1053/j.seminhematol.2022.10.002

Natural killer (NK)/T-cell lymphomas arise mainly from NK-cells and occasionally T-cells, and are universally infected with Epstein Barr virus (EBV). They are uncommon lymphomas more prevalent in Asian and Central/South American populations. NK/T-cel... Read More about Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management.

International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma (2022)
Journal Article
Khwaja, J., Kirkwood, A. A., Isbell, L. K., Steffanoni, S., Goradia, H., Pospiech, L., …Cwynarski, K. (2023). International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma. Haematologica, 108(3), 882-888. https://doi.org/10.3324/haematol.2022.281640

Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma (2022)
Journal Article
Wendler, J., Fox, C. P., Valk, E., Steinheber, C., Fricker, H., Isbell, L. K., …Illerhaus, G. (2022). Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma. BMC Cancer, 22(1), Article 971. https://doi.org/10.1186/s12885-022-09723-w

Background: Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (PCNSL) is a rare disorder with an increasing incidence over the past decades. High-level evidence has been reported for the MATRix regimen (high-dose methotrexat... Read More about Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.

Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group (2022)
Journal Article
Steffanoni, S., Calimeri, T., Laurenge, A., Fox, C. P., Soussain, C., Grommes, C., …Ferreri, A. J. M. (2022). Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group. British Journal of Haematology, 199(4), 507-519. https://doi.org/10.1111/bjh.18396

To optimise management of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection identifying high-risk patients and maintaining treatment dose intensity is an important issue in patients with aggressive lymphomas. In the present study... Read More about Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group.

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial (2022)
Journal Article
Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., Celico, C., …IELSG32 study investigators. (2022). Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia, 36(7), 1870-1878. https://doi.org/10.1038/s41375-022-01582-5

219 HIV-negative adults ≤70 years with primary CNS lymphoma (PCNSL) were enrolled in the randomized IELSG32 trial. Enrolled patients were randomly assigned to receive methotrexate-cytarabine (arm A), or methotrexate-cytarabine-rituximab (B), or metho... Read More about Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.

Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study (2022)
Journal Article
Lim, S. H., Stuart, B., Joseph-Pietras, D., Johnson, M., Campbell, N., Kelly, A., …Goldblatt, D. (2022). Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. Nature Cancer, 3(5), 552-564. https://doi.org/10.1038/s43018-022-00364-3

Patients with hematological malignancies are at increased risk of severe COVID-19 outcomes due to compromised immune responses, but the insights of these studies have been compromised due to intrinsic limitations in study design. Here we present the... Read More about Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study.

Rare central nervous system lymphomas (2022)
Journal Article
Kaji, F. A., Martinez‐Calle, N., Sovani, V., & Fox, C. P. (2022). Rare central nervous system lymphomas. British Journal of Haematology, 197(6), 662-678. https://doi.org/10.1111/bjh.18128

Central nervous system (CNS) lymphomas are rare malignancies characterised by lymphoid infiltration into the brain, spinal cord, cranial nerves, meninges and/or eyes in the presence or absence of previous or concurrent systemic disease. Most CNS lymp... Read More about Rare central nervous system lymphomas.

Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data (2021)
Journal Article
Halligan, S. J., Grainge, M. J., Martinez-Calle, N., Fox, C. P., & Bishton, M. J. (2022). Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data. British Journal of Haematology, 196(4), 932-938. https://doi.org/10.1111/bjh.17896

Systemic anaplastic large cell lymphoma (sALCL) is a rare T-cell lymphoma associated with poor prognosis after relapse. The immuno-conjugate Brentuximab Vedotin (BV) first became available for relapsed sALCL in England in 2013, following the results... Read More about Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data.

Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort (2021)
Journal Article
Martinez-Calle, N., Kirkwood, A. A., Lamb, M., Smith, A., Khwaja, J., Manos, K., …Fox, C. P. (2021). Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort. Advances in Therapy, 38(7), 3789-3802. https://doi.org/10.1007/s12325-021-01764-0

Introduction: Brentuximab vedotin (BV)-CHP is the new standard regimen for first-line treatment of systemic anaplastic large cell lymphoma (sALCL). We undertook a retrospective analysis of consecutive patients diagnosed with sALCL, treated in routine... Read More about Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.

Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP (2021)
Journal Article
Eyre, T. A., Wilson, W., Kirkwood, A. A., Wolf, J., Hildyard, C., Plaschkes, H., …Hatton, C. S. R. (2021). Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP. Blood Advances, 5(8), 2229-2236. https://doi.org/10.1182/bloodadvances.2021004286

Infection-related morbidity and mortality are increased in older patients with diffuse large B-cell lymphoma (DLBCL) compared with population-matched controls. Key predictive factors for infection-related hospitalization during treatment with rituxim... Read More about Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP.

Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma (2019)
Journal Article
Sorigue, M., Bishton, M., Domingo-Domenech, E., McMillan, A., Prusila, R., García, O., …Sancho, J. (2019). Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma. Leukemia & Lymphoma, 60(10), 2524-2531. https://doi.org/10.1080/10428194.2019.1594212

Short responses to immunochemotherapy predict for an inferior OS in follicular lymphoma. We set out to determine whether this is also the case in marginal zone lymphoma. A group of 139 marginal zone lymphoma (MZL) patients treated with front-line imm... Read More about Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma.

Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis (2018)
Journal Article
Martínez-Calle, N., Hartley, S., Ahearne, M., Kasenda, B., Beech, A., Knight, H., …Fox, C. P. (2019). Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis. British Journal of Haematology, 184(6), 957-968. https://doi.org/10.1111/bjh.15722

Delayed lymphocyte and T-cell immune reconstitution following bendamustine-rituximab (BR) for indolent non-Hodgkin lymphoma (iNHL) has been described, but no information is available for chronic lymphocytic leukaemia (CLL). We present a population-ba... Read More about Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.